Literature DB >> 20066559

Cyclin D3/CDK11(p58) complex involved in Schwann cells proliferation repression caused by lipopolysaccharide.

Yinong Duan1, Xingxin He, Huiguang Yang, Yuhong Ji, Tao Tao, Jinling Chen, Ling Hu, Fupeng Zhang, Xiaohong Li, Huimin Wang, Aiguo Shen, Xiang Lu.   

Abstract

Schwann cells proliferation is the main characterize of kinds PNS inflammation diseases. It has been well documented that cyclin D3 /CDK11(p58) complex inhibits cell function through multiple mechanisms, but the mechanism of cyclin D3/CDK11(p58) complex exerts its repressive role in the Schwann cells proliferation remains to be identified. In the present investigation, we demonstrated that the expression of CDK11(p58) were upregulated in the inflammation caused by LPS, a main part of bacteria. Cyclin D3 and the 58-kDa isoform of cyclin-dependent kinase 11 (CDK11(p58)) interacted with each other mainly in nuclear region, repressed Schwann cells proliferation and induced cell apoptosis. Overexpression of CDK11(p58) expression might enhance this process, while silence of cyclin D3 reverting it. This work demonstrates for the first time the role of cyclin D3/CDK11(p58) complex in repressing the Schwann cells proliferation and inducing its apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066559     DOI: 10.1007/s10753-009-9173-8

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  39 in total

1.  Identification and characterization of a novel cell cycle-regulated internal ribosome entry site.

Authors:  S Cornelis; Y Bruynooghe; G Denecker; S Van Huffel; S Tinton; R Beyaert
Journal:  Mol Cell       Date:  2000-04       Impact factor: 17.970

2.  Purification and characterization of a novel proline-directed protein kinase from bovine brain.

Authors:  J Lew; K Beaudette; C M Litwin; J H Wang
Journal:  J Biol Chem       Date:  1992-07-05       Impact factor: 5.157

3.  Role of the cell cycle in the pathobiology of central nervous system trauma.

Authors:  Ibolja Cernak; Bogdan Stoica; Kimberly R Byrnes; Simone Di Giovanni; Alan I Faden
Journal:  Cell Cycle       Date:  2005-09-15       Impact factor: 4.534

4.  Dopamine and glutamate induce distinct striatal splice forms of Ania-6, an RNA polymerase II-associated cyclin.

Authors:  J D Berke; V Sgambato; P P Zhu; B Lavoie; M Vincent; M Krause; S E Hyman
Journal:  Neuron       Date:  2001-10-25       Impact factor: 17.173

5.  Cyclin D3 is rate-limiting for the G1/S phase transition in fibroblasts.

Authors:  T Herzinger; S I Reed
Journal:  J Biol Chem       Date:  1998-06-12       Impact factor: 5.157

Review 6.  Ras/Raf/ERK signalling and NF1.

Authors:  Marie C Harrisingh; Alison C Lloyd
Journal:  Cell Cycle       Date:  2004-10-17       Impact factor: 4.534

7.  Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation.

Authors:  J Bartkova; J Lukas; M Strauss; J Bartek
Journal:  Oncogene       Date:  1998-08-27       Impact factor: 9.867

8.  Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-Kinase and Syk-mediated pathways.

Authors:  Patrick G Arndt; Naohito Suzuki; Natalie J Avdi; Kenneth C Malcolm; G Scott Worthen
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

9.  Association of Cdk-activating kinase subunits with transcription factor TFIIH.

Authors:  H Serizawa; T P Mäkelä; J W Conaway; R C Conaway; R A Weinberg; R A Young
Journal:  Nature       Date:  1995-03-16       Impact factor: 49.962

10.  Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  D Orlikowski; B Chazaud; A Plonquet; F Poron; T Sharshar; P Maison; J-C Raphaël; R K Gherardi; A Créange
Journal:  J Neuroimmunol       Date:  2003-01       Impact factor: 3.478

View more
  7 in total

1.  Identification and characterization of the BmCyclin L1-BmCDK11A/B complex in relation to cell cycle regulation.

Authors:  Tai-Hang Liu; Yun-Fei Wu; Xiao-Long Dong; Cai-Xia Pan; Guo-Yu Du; Ji-Gui Yang; Wei Wang; Xi-Yan Bao; Peng Chen; Min-Hui Pan; Cheng Lu
Journal:  Cell Cycle       Date:  2017-03-20       Impact factor: 4.534

2.  CDK11(p58) promotes rat astrocyte inflammatory response via activating p38 and JNK pathways induced by lipopolysaccharide.

Authors:  Xiaojuan Liu; Chun Cheng; Bai Shao; Xiaohong Wu; Yuhong Ji; Yichang Liu; Xiang Lu; Aiguo Shen
Journal:  Neurochem Res       Date:  2011-11-27       Impact factor: 3.996

Review 3.  The CDK inhibitors in cancer research and therapy.

Authors:  Jonas Cicenas; Mindaugas Valius
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-30       Impact factor: 4.553

4.  FBXL2 is a ubiquitin E3 ligase subunit that triggers mitotic arrest.

Authors:  Bill B Chen; Jennifer R Glasser; Tiffany A Coon; Rama K Mallampalli
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

5.  F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest.

Authors:  B B Chen; J R Glasser; T A Coon; R K Mallampalli
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

Review 6.  Highlights of the Latest Advances in Research on CDK Inhibitors.

Authors:  Jonas Cicenas; Karthik Kalyan; Aleksandras Sorokinas; Asta Jatulyte; Deividas Valiunas; Algirdas Kaupinis; Mindaugas Valius
Journal:  Cancers (Basel)       Date:  2014-10-27       Impact factor: 6.639

7.  CDK11 Promotes Cytokine-Induced Apoptosis in Pancreatic Beta Cells Independently of Glucose Concentration and Is Regulated by Inflammation in the NOD Mouse Model.

Authors:  Ester Sala; Celia Vived; Júlia Luna; Noemí Alejandra Saavedra-Ávila; Upasana Sengupta; A Raúl Castaño; Sabrina Villar-Pazos; Laura Haba; Joan Verdaguer; Ana B Ropero; Thomas Stratmann; Javier Pizarro; Manuel Vázquez-Carrera; Angel Nadal; Jill M Lahti; Conchi Mora
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.